IL112895A - Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists - Google Patents

Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists

Info

Publication number
IL112895A
IL112895A IL11289595A IL11289595A IL112895A IL 112895 A IL112895 A IL 112895A IL 11289595 A IL11289595 A IL 11289595A IL 11289595 A IL11289595 A IL 11289595A IL 112895 A IL112895 A IL 112895A
Authority
IL
Israel
Prior art keywords
obsessive
antagonists
treatment
pharmaceutical compositions
compulsive disorders
Prior art date
Application number
IL11289595A
Other languages
English (en)
Other versions
IL112895A0 (en
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of IL112895A0 publication Critical patent/IL112895A0/xx
Publication of IL112895A publication Critical patent/IL112895A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
IL11289595A 1994-03-09 1995-03-06 Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists IL112895A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/209,084 US5618824A (en) 1994-03-09 1994-03-09 Treatment of obsessive-compulsive disorders with 5-HT2 antagonists

Publications (2)

Publication Number Publication Date
IL112895A0 IL112895A0 (en) 1995-06-29
IL112895A true IL112895A (en) 1999-12-31

Family

ID=22777257

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11289595A IL112895A (en) 1994-03-09 1995-03-06 Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists

Country Status (15)

Country Link
US (1) US5618824A (fr)
EP (1) EP0749309A1 (fr)
JP (1) JP3861250B2 (fr)
KR (1) KR100360132B1 (fr)
CN (1) CN1143321A (fr)
AU (1) AU690968B2 (fr)
CA (1) CA2183954C (fr)
FI (1) FI963511A7 (fr)
HU (1) HU218948B (fr)
IL (1) IL112895A (fr)
NO (1) NO963731L (fr)
NZ (1) NZ281768A (fr)
TW (1) TW301606B (fr)
WO (1) WO1995024194A1 (fr)
ZA (1) ZA951797B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018602A1 (fr) * 1990-06-01 1991-12-12 Merrell Dow Pharmaceuticals Inc. (+)-α-(2,3-DIMETHOXYPHENYLE)-1-[2-(4-FLUOROPHENYLE)ETHYLE]-4-PIPERIDINEMETHANOL
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
EP0796619A1 (fr) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Utilisation de (+)-alpha-(2,3-diméthoxyphényle)-1-(2-(4-fluorophényle)éthyle)-4-pipéridineméthanol pour le traitement des troubles dépressifs et bipolaires
AU2606897A (en) 1996-04-05 1997-10-29 Fmc Corporation Method for preparing spinel li1+xmn2-xo4+y intercalation compounds
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6228864B1 (en) * 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US20050261341A1 (en) * 1998-03-13 2005-11-24 Aventis Pharmaceuticals Inc. Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
SE9801516D0 (sv) 1998-04-30 1998-04-30 Maria Carlsson M100907/4-Piperidinemethanol derivatives for autism
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
HRP20010140A2 (en) * 1998-08-28 2002-02-28 Aventis Pharma Inc THE USE OF R(+)-<F128M>a<F255D>-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
PT1202967E (pt) * 1999-07-16 2007-02-28 Aventis Pharma Inc Éster mono-[3-({1-[2-(4-fluoro-fenil)-etil]-piperidin-4-il}-hidroxi-metil)-2-metoxi-fenílico] do áçido sulfúrico
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
JP2008520666A (ja) * 2004-11-22 2008-06-19 マリンクロッド・インコーポレイテッド ベンズフェタミン塩酸塩の精製方法
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
EP3468545B1 (fr) 2016-06-08 2026-08-05 President and Fellows of Harvard College Procédés et compositions pour réduire le dysfonctionnement tactile et l'anxiété associés au trouble du spectre de l'autisme, au syndrome de rett et au syndrome de l'x fragile
WO2019226808A1 (fr) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions et procédés permettant de réduire un dysfonctionnement tactile, l'anxiété et une déficience sociale
EP3801512A4 (fr) 2018-05-29 2022-01-19 President and Fellows of Harvard College Compositions et méthodes pour réduire un dysfonctionnement tactile, l'anxiété et une déficience sociale
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US20220233133A1 (en) * 2019-05-22 2022-07-28 President And Fellows Of Harvard College Human tactile prepulse inhibition assay
WO2021261471A1 (fr) * 2020-06-23 2021-12-30 国立大学法人京都大学 Substance thérapeutique pour trouble obsessionnel compulsif

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
EP0436245A1 (fr) * 1989-12-27 1991-07-10 Duphar International Research B.V Benzimidazol-2(1H)-ones-3,4-pontées et substituées
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5264576A (en) * 1992-10-22 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Pyrazolo[4,3-c]pyridines which are intermediates
WO1994014801A1 (fr) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Derives heterocycliques de l'uree antagonistes de 5ht2c et 5h¿2b?
AU7177694A (en) * 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
EP0749309A1 (fr) 1996-12-27
HU218948B (hu) 2001-01-29
CA2183954A1 (fr) 1995-09-14
IL112895A0 (en) 1995-06-29
ZA951797B (en) 1996-12-03
NZ281768A (en) 2001-02-23
JP3861250B2 (ja) 2006-12-20
CN1143321A (zh) 1997-02-19
US5618824A (en) 1997-04-08
TW301606B (fr) 1997-04-01
AU690968B2 (en) 1998-05-07
FI963511A0 (fi) 1996-09-06
KR100360132B1 (ko) 2003-08-02
FI963511L (fi) 1996-09-06
NO963731D0 (no) 1996-09-06
WO1995024194A1 (fr) 1995-09-14
KR970701544A (ko) 1997-04-12
CA2183954C (fr) 2000-07-18
JPH09510441A (ja) 1997-10-21
HUT75317A (en) 1997-05-28
FI963511A7 (fi) 1996-09-06
NO963731L (no) 1996-11-06
HU9602449D0 (en) 1996-11-28
AU1869495A (en) 1995-09-25

Similar Documents

Publication Publication Date Title
HUP9904525A3 (en) Pharmaceutical compositions for the treatment of neurological disorders comprising s-(-)-n-propargyl-1-amino indan
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
HU9602449D0 (en) Treatment of obsessive-compulsive disorders with 5-ht2 antagonists
HUP0101627A3 (en) Pharmaceutical compositions for treating neuropsychiatric disorders
HUP9701193A3 (en) Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
IL121170A0 (en) Compositions for the treatment of dermatological disorders
HUP0104676A3 (en) Compositions for the treatment of anorectal disorders and their use
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
HUP0004412A3 (en) Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders
HUP9801995A3 (en) Substituted pyrimidine-thioalkyl and alkylether compounds and their use for producing pharmaceutical compositions
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
IL143921A0 (en) Compositions for the treatment and prevention of tumors and tumor-related disorders
HUP0200287A3 (en) Pharmaceutical compositions for the treatment of neurological or neuropsychiatric disorders
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
HUP9902405A3 (en) Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis
HUP0200284A3 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them
HUP0103832A3 (en) Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof
IL119225A (en) Pharmaceutical compositions for the treatment of asthma in mammals
HUP0004588A3 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-oles, method for the production and use thereof as medicaments and pharmaceutical compositions containing them
AU686084B3 (en) Pharmaceutical compositions for the treatment of depressive disorders
IL120005A0 (en) Pharmaceutical compositions for the treatment of the eye
IL116826A (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions for treatment or prophylaxis of obesity

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
HC Change of name of proprietor(s)

Owner name: AVENTIS INC.

Free format text: FORMER NAME:MERRELL PHARMACEUTICALS INC.

KB Patent renewed
KB Patent renewed
EXP Patent expired